Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Kodak Stock Skyrocketed 75% in 2020

By Keith Noonan - Jan 4, 2021 at 9:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The century-old camera company was one of last year's most exciting and controversial stocks.

What happened

Shares of Eastman Kodak ( KODK -5.84% ) rose 75% across last year's trading, according to data from YCharts. The stock soared following indications that the company would be making a big push into the production of chemicals used in pharmaceutical manufacturing. 

KODK Chart

KODK data by YCharts

News hit in late July that Kodak had received approval for a $765 million loan from the U.S. International Development Finance Corporation (DFC). The loan was part of the Defense Production Act and was intended to jump-start the company's pivot to making chemicals used in the manufacturing of pharmaceuticals, including hydroxychloroquine -- a compound touted by the Trump administration and some doctors as a treatment for mitigating the effects of COVID-19. What followed was one of the most volatile and exciting stock market stories of 2020. 

Golden bull and bear figurines facing each other.

Image source: Getty Images.

So what

Kodak is best known for its camera and film businesses, but the company also operates a chemicals production segment. With its core film-based unit facing intense pressures from the rise of digital technologies, the business has struggled to find ways to grow over the last decade.

The $765 million loan to accelerate chemicals production was a potential game changer for Kodak. The company's stock soared roughly 3,000% following the announcement, and it closed out July up 879.8%, according to data from S&P Global Market Intelligence

However, controversy and volatility followed, and the DFC and Kodak announced that there would be a pause on the process after the loan attracted scrutiny. The Securities and Exchange Commission (SEC) announced it would conduct a review of the potentially illegal insider trading among top Kodak executives leading up to the announcement of the loan. Democrats in the U.S. House of Representatives also announced that they would be launching an investigation.

Kodak gave up most of the gains it had notched shortly after the loan's announcement, but more twists and turns were on the way. The stock saw volatile swings in relation to news surrounding the loan and related insider trading investigations, but it still closed out the year with impressive gains. 

Now what

A special committee hired by Kodak found no wrongdoing among the company's executives, and an internal review conducted by the DFC found that it had committed no wrongdoing in awarding the loan. For now, it looks like Kodak may be in the clear, and it plans to move forward with its chemicals push regardless of what happens with the $765 million loan.

However, whether the company's pivot to pharmaceutical chemicals production will be successful is still uncertain. Manufacturing chemical ingredients for generic pharmaceuticals is typically a low-margin business, and reorienting the business will likely prove to be a challenging undertaking.

With the core film segment likely to continue declining over the long term, the potential new growth avenue is a welcome development. However, investors should probably continue with the assumption that Kodak stock will likely continue to see volatile trading in the near term. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eastman Kodak Stock Quote
Eastman Kodak
$5.64 (-5.84%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.